• Genmab will present data from its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 29–June 2.
• The company will also attend the European Hematology Association (EHA) 2026 Congress in Stockholm on June 11–14.
• Key readouts include Phase 3 results for epcoritamab in relapsed or refractory large B-cell lymphoma, with additional Phase 3 updates in follicular lymphoma.
• Late-stage pipeline programs rinatabart sesutecan and petosemtamab will be featured in trial-in-progress presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.